Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Treatment of Parkinson's Disease May Depend on Augmented Enzyme Activity

By BiotechDaily International staff writers
Posted on 07 Jul 2009
A naturally occurring brain enzyme has been identified that promotes the breakdown of the toxic protein clumps that characterize familial Parkinson's disease (PD) and some sporadic forms of the disease.

Dominantly inherited mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are the most common cause of familial PD and have also been identified in individuals with sporadic PD. Although the exact cellular function of LRRK2 remains unknown, most PD-linked mutations appear to be toxic to cells in culture via mechanisms that depend on the kinase activity of LRRK2 or on the formation of cytoplasmic inclusions.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) reported in the June 17, 2009, online edition of the journal Public Library of Science (PLoS) One that they had identified an E3 ubiquitin ligase known as CHIP, which physically associated with LRRK2. CHIP regulated the cellular abundance of LRRK2 by forming a complex with LRRK2 and another protein; Hsp90. CHIP regulated LRRK2 through a process of ubiquitination and proteasome-dependent degradation.

"CHIP may be a useful therapeutic target for treatments to break down LRRK2 in people with Parkinson's," said senior author Dr. Matthew Goldberg, assistant professor of neurology and psychiatry at the University of Texas Southwestern Medical Center. "Our next step is to identify cellular mechanisms that signal LRRK2 to be degraded by CHIP or by other mechanisms. Because LRRK2 mutations are believed to cause Parkinsonism by increasing the activity of LRRK2, enhancing the normal mechanisms that target LRRK2 for degradation by CHIP may be therapeutically beneficial."
"There are currently enormous efforts to identify potential therapies based on inhibiting this mutated protein," said Dr. Goldberg. "Our paper is a major advance because we identify a protein that binds to the mutated protein and promotes its breakdown."

Related Links:
University of Texas Southwestern Medical Center





comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.